secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001437749-24-035521
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Q3 net operating loss down 74% to $1.6M; on track for NDA filings by year-end
--------------------------------------------------------------------------------

- Net operating loss $1.6M in Q3 2024 vs $6.1M in Q3 2023; nine-month net loss $16.1M vs $25.8M.
- Cash $1.6M at Sep 30; closed $5.4M second tranche from Anson Funds post-quarter; $10.8M total convertible debt.
- Expects to file NDAs for NRX-100 (IV ketamine) and NRX-101 (bipolar depression) by end of 2024, with 2025 PDUFA dates.
- HOPE Therapeutics signed two non-binding LOIs to acquire Interventional Psychiatry Clinics; first revenue forecast by year-end 2024.
- Retired Streeterville debt at substantial discount; litigation settled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924035521/0001437749-24-035521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924035521/nrxp20241115_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer